Literature DB >> 11745430

Active immunization against cancer with dendritic cells: the near future.

R M Steinman1, M Dhodapkar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745430     DOI: 10.1002/ijc.1503

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  70 in total

Review 1.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  Autoantigen-specific protection of non-obese diabetic mice from cyclophosphamide-accelerated diabetes by vaccination with dendritic cells.

Authors:  T Krueger; U Wohlrab; M Klucken; M Schott; J Seissler
Journal:  Diabetologia       Date:  2003-08-20       Impact factor: 10.122

Review 4.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

5.  Production of functional dendritic cells from menstrual blood--a new dendritic cell source for immune therapy.

Authors:  Pham Van Phuc; Dang Hoang Lam; Vu Bich Ngoc; Duong Thi Thu; Nguyen Thi Minh Nguyet; Phan Kim Ngoc
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-03-18       Impact factor: 2.416

6.  Role of dendritic cells in progression and clinical outcome of colon cancer.

Authors:  Maya V Gulubova; Julian R Ananiev; Tatyana I Vlaykova; Yovcho Yovchev; Vanya Tsoneva; Irena M Manolova
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

7.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

8.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

9.  Antitumor activity of G3139 lipid nanoparticles (LNPs).

Authors:  Xiaogang Pan; Li Chen; Shujun Liu; Xiaojuan Yang; Jian-Xin Gao; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

Review 10.  Dendritic cell based vaccination strategy: an evolving paradigm.

Authors:  Anna C Filley; Mahua Dey
Journal:  J Neurooncol       Date:  2017-04-22       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.